From Mercola Data from 561 patients diagnosed with mild to moderate Alzheimers was assessed in this double-blind, placebo-controlled, parallel-group, randomized clinical trial. Participants were divided into four groups, and received either: •2,000 IUs per day of vitamin E •20 mg per day of the drug memantine •A combination of vitamin E and mematine •Placebo Follow up was just over two years. Results showed that clinical progression of Alzheimers slowed by 19 percent per year in the group receiving vitamin E, compared with placebo. (This delay translated into just over six months of delayed progression over the two-year follow-up period.) Caregiver time also increased the least in the group receiving vitamin E. This does not mean vitamin E prevents the disease, but it appears it might allow patients to retain their independence a bit longer. The authors concluded that: Patients with mild to moderate Alzheimers Disease (AD), 2,000 IU/day of alpha tocopherol compared with placebo resulted in slower functional decline. There were no significant differences in the groups receiving memantine alone or memantine plus alpha tocopherol. These findings suggest benefit of alpha tocopherol in mild to moderate AD by slowing functional decline and decreasing caregiver burden.
Posted on: Fri, 31 Jan 2014 13:11:54 +0000
Trending Topics
Recently Viewed Topics
© 2015